海南海藥(000566.SZ):控股股東與華同實業簽署股份轉讓協議及債務轉移協議等
格隆匯12月12日丨海南海藥(000566.SZ)公佈,公司近日收到控股股東南方同正的通知,南方同正與華同實業於2019年12月12日分別簽署了《關於
<海南華同實業有限公司出資協議>
及其補充協議的終止協議》、《深圳市南方同正投資有限公司與海南華同實業有限公司關於海南海藥股份轉讓的協議》、《深圳市南方同正投資有限公司與海南華同實業有限公司關於債務轉移的協議》。
海南華同實業有限公司出資協議>
南方同正擬根據之前《控制權收購協議》的約定將其所持海南海藥約2.0303億股無限售流通股轉讓給華同實業。每股轉讓價為6.19元/股,轉讓價款合計為人民幣約12.57億元。
醫藥控股擬收購海南海藥控制權事宜,有關各方於2019年4月30日簽署了《控制權收購協議》,就南方同正將其所持海南海藥約2.0303億股無限售流通股及以該等股份質押式回購形成的負債(包括本金和利息,“目標負債”)以股東出資或轉讓的方式注入新設SPV公司,醫藥控股擬通過收購SPV公司100%。股權取得海南海藥控制權及相關合作事宜與安排進行了約定。華同實業係為實施《控制權收購協議》而設立的SPV公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.